Pfizer's combination therapy improves survival in bladder cancer trial
The interim results from an ongoing late-stage trial of the combination therapy showed significant improvement in event-free survival – which measures how long a patient remains free from disease recurrence – and overall survival when compared to surgery alone, the company said.
"These latest results underscore the practice-changing potential of this combination in earlier stages of bladder cancer, where it has the potential to improve outcomes for even more patients," said Johanna Bendell, Pfizer's oncology chief development officer.
In muscle-invasive bladder cancer, the tumor extends beyond the inner lining and penetrates the muscular wall of the organ. It accounts for about 25% of all newly diagnosed bladder cancers and is a particularly aggressive form with a high risk of spreading, according to the National Institutes of Health.
Pfizer said it plans to discuss the trial results with global health authorities for potential regulatory filings.
The combination therapy leverages anti-PD-1 treatments that block the PD-1 protein to help the immune system combat cancer, where Padcev, an antibody-drug conjugate, targets specific cancer cells without damaging healthy ones.
Padcev, co-developed with Japan's Astellas (4503.T), opens new tab, was approved by the U.S. Food and Drug Administration in 2019 to treat patients with a form of bladder cancer called metastatic urothelial cancer.
The drug brought $1.59 billion in sales last year, contributing about 2% of Pfizer's total revenue.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
30 minutes ago
- The Independent
AI could soon detect early voice box cancer from the sound of your voice
AI could soon be able to tell whether patients have cancer of the voice box using just a voice note, according to new research. Scientists recorded the voices of men with and without abormalities in their vocal folds - which can be an early sign of laryngeal cancer - and found differences in vocal qualities including pitch, volume, and clarity. They now say AI could be used to detect these 'vocal biomarkers', leading to earlier, less invasive diagnosis. Researchers at Oregon Health and Science University believe voice notes could now be used to train an AI tool that recognises vocal fold lesions. Using 12,523 voice recordings from 306 participants across North America, they found distinctive vocal differences in men suffering from laryngeal cancer, men with vocal fold lesions, and men with healthy vocal folds. However, researchers said similar hallmark differences were not detected in women. They are now hoping to collect more recordings of people with and without the distinctive vocal fold lesions to create a bigger dataset for tools to work from. In the UK, there are more than 2,000 new cases of laryngeal cancer each year. Symptoms can include a change in your voice, such as sounding hoarse, a high-pitched wheezing noise when you breathe, and a long-lasting cough. 'Here we show that with this dataset we could use vocal biomarkers to distinguish voices from patients with vocal fold lesions from those without such lesions,' said Dr Phillip Jenkins, the study's corresponding author said. 'To move from this study to an AI tool that recognises vocal fold lesions, we would train models using an even larger dataset of voice recordings, labeled by professionals. We then need to test the system to make sure it works equally well for women and men. 'Voice-based health tools are already being piloted. Building on our findings, I estimate that with larger datasets and clinical validation, similar tools to detect vocal fold lesions might enter pilot testing in the next couple of years," he predicted. It comes after research from US-based Klick Labs, which created an AI model capable of distinguishing whether a person has Type 2 diabetes from six to 10 seconds of voice audio. The study involved analysing 18,000 recordings in order to identify acoustic features that differentiated non diabetics from diabetics and reported an 89 per cent accuracy rating for women and 86 per cent for men. Jaycee Kaufman, a research scientist at Klick Labs, praised the future potential for AI-powered voice tools in healthcare, saying: 'Current methods of detection can require a lot of time, travel and cost. Voice technology has the potential to remove these barriers entirely.'
BBC News
31 minutes ago
- BBC News
Spireites co-owner Phil Kirk in palliative care
Chesterfield co-owner Phil Kirk has entered palliative care after treatment for his inoperable cancer was League Two side announced in March this year that the 59-year-old, who first invested in the club in 2022 with his brother and co-owner Ashley, had been diagnosed with cancer."Phil and his family remain deeply committed to the ongoing support of the club and its community," they said in a statement., external"The club will continue to operate as normal, and we are united in ensuring Phil's vision and values remain at the heart of everything we do."Chesterfield finished seventh in League Two last season and have won their opening two games this campaign.
Medical News Today
37 minutes ago
- Medical News Today
Subtle signs of multiple sclerosis may appear years before onset
Research is ongoing regarding when multiple sclerosis develops and strategies for prompt diagnosis. A recent study found that people who went on to develop multiple sclerosis had a much higher use of medical services up to 15 years prior to multiple sclerosis onset. The results suggest that multiple sclerosis develops earlier than researchers thought in the past, and could help with earlier management of the condition. According to the National Institute of Neurological Disorders and Stroke, 'multiple sclerosis (MS) is a chronic neurological disorder.' There are multiple types, and people can experience symptoms like cognitive changes, vision changes, and even paralysis. A study recently published in JAMA Network Open looked at the use of healthcare services in the 25 years before MS symptom to a matched cohort of participants without MS, participants with this condition used healthcare services more than their peers in the 15 years before MS were able to identify specific visit reasons in certain timeframes, with mental health concerns and ill-defined signs and symptoms being some of the earliest results suggest that MS starts earlier, which may help with diagnosis and early intervention for the condition. What does medical treatment look like before MS diagnosis?For this research, experts wanted to learn more about the prodromal phase that may happen in MS, particularly looking at even earlier data than what has been previously studied. The study was conducted in British Columbia, Canada, and researchers used insurance data. They looked at hospital and doctor visits. They used the British Columbia MS clinical database to learn when participants first had MS symptoms. Researchers also had access to data on filled prescriptions and population data. Researchers were able to look at data from 2,038 participants with MS, as well as a matched cohort of 10,182 participants who did not have MS. After looking at the doctor visit rates each year in the 25 years prior to MS onset, researchers honed in on the 15 years before. This was when changes in health care visits the 15 years before MS onset, researchers identified more visits from MS participants for ill-defined signs and symptoms. In the 14 years before MS onset, researchers identified an increase in doctor visits, doctor visits related to mental health, and injury-related visits. The elevation in mental health visits was significant for most of the 14 years prior to MS onset, with the exception of years 7, 5, and 4. Overall, mental health visits were up 76%. Twelve years before MS onset, there started to be an increase in psychiatric visits, and this remained significant except in years 6 to 8, and year 4 before MS onset. Overall, the increase in psychiatric consultations was 159%. Increase in ophtalmology, nervous system-related doctor's appointmentsOphthalmology visits were increased 9 years before MS onset, except at year 6 and year 2, with the highest increase the year right before MS onset. In the 8 years before MS continued to be high prior to MS onset except at year 7 and year 5. The greatest spike was in the year right before MS onset. Visits for musculoskeletal-related problems were increased in the five years before MS year four and in the year leading up to MS onset, there was also an increase in visits for nervous system conditions, with a greater increase in the year before MS onset. Visits to the emergency room were greater 5 years before MS onset, radiology increased 3 years before, and internal medicine and neurosurgery increased one year before. Many healthcare visit upticks peaked in the year right before MS onset. For example, doctor visits and visits for injury, ill-defined signs and symptoms, sensory-organ concerns, and musculoskeletal-related problems peaked in the year before MS onset. Other types of visits were affected in specific years. For example, endocrine visits increased in year 9 prior to the onset of MS. At the same time, visits related to pregnancy and childbirth decreased to a significant level in years 2 and conditions also had distinct increases prior to MS onset. For example, researchers observed increases in anxiety and depression at years 4, 3 and 2. In the 2 years before MS onset, there was an increase in problems like dizziness and the year before MS onset, there was an increase in migraines and specific eye problems, such as retinal detachment. This data supports the idea that MS may start much sooner than experts previously believed and indicates the need for more research. The authors suggest that psychiatric and mental health concerns may be early features of the prodromal phase of MS, because these concerns started years before increases in visits related to the nervous system. Risk of MS overdiagnosis?While this research did allow for extensive follow-up, there are still limitations. First of all, researchers did not have data on some clinical information details. Instead, they had information on why participants sought out health care services. Second, there is some risk for misclassification or miscoding based on the data researchers used. There are also challenges of determining MS symptom onset, and researchers note that this 'may be influenced by recall bias and challenges with medical history taking.' Some participants had a claim for a demyelinating event or MS before the date designated as the 'MS symptom onset date.'It is possible there were some cases of MS that doctors could have diagnosed earlier. It's also possible that participants in the matched cohort had MS, in spite of evidence against this. This data focused on people with MS in British Columbia, Canada, and the majority of participants with MS were female, limiting researchers did not collect data on race or ethnicity, so more data specifying this could be helpful. They only corrected for some factors in the statistical analysis, which could have impacted the results. Burcu Zeydan, MD, an assistant professor of neurology at Mayo Clinic, who was not involved in this research noted the following cautions to Medical News Today: 'We see that healthcare visits in the 'pre-MS diagnosis' period are mainly for rather nonspecific and/or common causes such as headaches, fatigue, and mental health issues. Since most of these individuals will never develop MS, identification of individuals in a possible MS prodrome carries the risk for overdiagnosis and overtreatment as well as a concern for causing unnecessary distress for individuals and families. There is also a possibility of missed opportunities for earlier recognition of MS by clinicians, which is supported by the rise in ophthalmology and neurology visits in the current study as pointed out by the authors. These should be considered in evaluating the MS prodrome.''MS may start earlier than previously thought'The research implies that MS starts earlier and delves into deeper questions about what may cause the condition. Study author Professor Helen Tremlett, PhD, in the Faculty of Medicine (Neurology) at the University of British Columbia, Canada, explained to MNT that:'MS may start earlier than we previously thought, and that is actually really important when we think about what causes MS… Our findings suggest we need to look back much further in time than we do, perhaps currently, to avoid thinking that something might cause MS, when, in actual fact, the disease has already started… There's potential here in the future, not currently, to recognize and perhaps diagnose and manage MS earlier than we can do currently, with the view of course of preventing or slowing progression of the disease.'Zeydan noted that, 'using the observations related to MS prodrome, [researchers] should aim to develop individual-level risk models, possibly a scoring system to reliably identify individuals that are at high risk for developing MS.''Biomarkers (blood and imaging) would be the key to this effort,' she told us. 'Perhaps age and sex differences and tools such as AI can help finetune MS risk prediction models,' Zeydan further hypothesized.'With a potential future multimodal biomarker panel, if people at high risk can be effectively identified in the MS prodrome, individualized disease screening methods can be implemented into MS care for these high-risk individuals,' she concluded.
